前立腺がん治療の世界市場2016-2026

◆英語タイトル:The Prostate Cancer Market 2016-2026
◆商品コード:VGAIN60627
◆発行会社(調査会社):visiongain
◆発行日:2016年4月
◆ページ数:228
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、前立腺がん治療の世界市場について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2. 前立腺がんの概要

3. 前立腺がん治療市場 2016-2026

4. 前立腺がん治療薬市場 2016-2026

5. 前立腺がん治療機器市場 2016-2026

6. 前立腺がん治療市場における主要企業 2016

7. 主要国市場 2016-2026

8. 前立腺がん治療市場の定性分析 2016-2026

9. 結論

10. 用語集
【レポートの概要】

What can be expected from the prostate cancer market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 228-page report provides 213 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole prostate cancer therapeutics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

The report also includes revenue forecasts to 2026 for the following submarkets in the prostate cancer market:
• Prostate Cancer Drugs – including revenue forecasts to 2026 for:
• Zytiga
• Xtandi
• Leuplin
• Lupron
• Jevtana
• Zoladex
• Casodex
• Xofigo
• Taxotere

• Prostate Cancer Devices – including revenue forecasts to 2026 for:
• Radical Prostatectomy
• External Beam Radiation Therapy
• Brachytherapy
• High-Intensity Focused Ultrasound (HIFU)
• Cryotherapy

The report also includes revenue forecasts to 2026 for the following national and regional markets for prostate cancer:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• India
• Russia
• Brazil
• South Korea

The report provides detailed profiles of key companies operating within the prostate cancer market:
• Johnson & Johnson
• AstraZeneca
• Sanofi
• AbbVie
• Varian Medical Systems
• Elekta
• Theragenics

Leading companies and potential for market growth
Overall revenue for the prostate cancer market will reach $12.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in prostate cancer devices, treatments with more favourable side effect profiles and the launch of several new therapies in both early and late stage prostate cancer will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain’s analysis of 7 leading companies, including these:
• Johnson & Johnson
• AstraZeneca
• Sanofi
• AbbVie
• Varian Medical Systems
• Elekta
• Theragenics
A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years (where available)
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the prostate cancer therapeutics industry?
Our new report discusses issues and events affecting the prostate cancer therapeutics market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Prostate Cancer Market 2016-2026 report helps you
In summary, our 228-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Prostate Cancer market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading prostate cancer products in the following areas: prostate cancer drugs and prostate cancer devices.
• Revenue forecasts to 2026 for 9 leading drugs – discover prospects for leading prostate cancer drugs including: Zytiga, Xtandi, Leuplin, Lupron, Jevtana, Zoladex, Casodex, Xofigo and Taxotere
• Revenue forecasts to 2026 for 5 leading device markets – discover prospects for leading prostate cancer device including: Radical Prostatectomy, External Beam Radiation Therapy, Brachytherapy, High-Intensity Focused Ultrasound (HIFU) and Cryotherapy devices
• Revenue forecasts to 2026 for twelve leading national markets – US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
• Assessment of 7 leading companies – analysis of products, revenue, mergers & acquisitions, sales by region and products
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the prostate cancer market and leading companies. You will find data, trends and predictions. Please order our report now.

【レポートの目次】

1. Report Overview
1.1. The Prostate Cancer Therapeutics Market Overview
1.2. Prostate Cancer Therapeutics Market Segmentation
1.3. Why You Should Read This Report
1.4. How This Report Delivers
1.5. Key Questions Answered by This Analytical Report
1.6. Who is This Report For?
1.7. Methodology
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Reports
1.10. About Visiongain

2. Introduction to Prostate Cancer
2.1. What Is Cancer?
2.2. Phenotypic Characteristics of Cancer Cells
2.2.1. Uncontrolled Growth
2.2.2. Loss of Functioning Apoptotic Pathways
2.2.3. Lack of Differentiation
2.2.4. Increased Angiogenesis
2.2.5. Potential for Metastasis
2.2.6. Genetic Instability
2.3. What Causes Cancer?
2.3.1. Worldwide Prevalence of Cancer: A Global Picture
2.4. What is Prostate Cancer?
2.4.1. Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.4.2. Risk Factors for Prostate Cancer
2.5. How is Prostate Cancer Diagnosed?
2.5.1. PSA Testing
2.5.2. Digital Rectal Examination Testing
2.5.3. Prostate Cancer Screening: Does the Cost Justify the Means?
2.5.4. Alternative Tests Could Change Diagnostics
2.6. Treating Prostate Cancer
2.6.1. Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.6.1.1. Brachytherapy
2.6.1.2. Radical Prostatectomy
2.6.1.3. External Beam Radiation Therapy
2.6.1.4. Cryotherapy
2.6.1.5. High-Intensity Focused Ultrasound (HIFU)
2.6.2. Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.6.3. Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.6.4. Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.6.5. First Line Chemotherapy: Docetaxel is a Standard Treatment
2.6.6. Post Docetaxel Therapy: Five FDA Approved Drugs
2.6.7. Second Line Chemotherapy: Jevtana Approved in 2010

3. The Prostate Cancer Therapeutics Market 2016-2026
3.1. The Global Prostate Cancer Therapeutics Market, 2014
3.2. The Global Prostate Cancer Therapeutics Market Forecast, 2016-2026
3.3. The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2016-2026

4. The Prostate Cancer Drugs Market 2016-2026
4.1. The Prostate Cancer Drugs Market: Greater Choice of Drugs Increasing Competition in the mCRPC Setting
4.2. The Prostate Cancer Drugs Market, 2015
4.3. Leading Prostate Cancer Drugs: Market Forecast, 2015-2025
4.4. Market Share of Leading Prostate Cancer Drugs, 2016-2026
4.5. First Generation Chemotherapies
4.5.1. Taxotere (Sanofi)s
4.5.1.1. Taxotere Sales, 2014
4.5.1.2. Taxotere Sales Forecast, 2016-2026
4.6. Second Generation Chemotherapies
4.6.1. Jevtana (Sanofi)
4.6.1.1. Jevtana Sales, 2014 & 2015
4.6.1.2. Jevtana Sales Forecast, 2016-2026
4.7. First Generation Hormones
4.7.1. Casodex (AstraZeneca)
4.7.1.1. Casodex Sales, 2014 & 2015
4.7.1.2. Casodex Sales Forecast, 2016-2026
4.7.2. Leuplin (Takeda) / Lupron (AbbVie)
4.7.2.1. Leuplin & Lupron Sales, 2014 & 2015
4.7.2.2. Leuplin & Lupron Sales Forecast, 2016-2026
4.7.3. Zoladex (AstraZeneca)
4.7.3.1. Zoladex Sales, 2014 & 2015
4.7.3.2. 2 Zoladex Sales Forecast, 2015-2025
4.8. Second Generation Hormones
4.8.1. Zytiga (Johnson & Johnson)
4.8.1.1. Zytiga Sales, 2014 & 2015
4.8.1.2. Zytiga Sales Forecast, 2016-2026
4.8.2. Xtandi (Medivation/ Astellas Pharma)
4.8.2.1. Xtandi Sales, 2014 & 2015
4.8.2.2. Xtandi Sales Forecast, 2016-2026
4.9. Radiopharmaceuticals
4.9.1. Xofigo (Bayer)
4.9.1.1. Xofigo Sales, 2014 & 2015
4.9.1.2. Xofigo Sales Forecast, 2016-2026
4.10. Other Drugs
4.11. Prostate Cancer Drugs Pipeline, 2016
4.11.1. Phase III Development
4.11.1.1. DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2. Tookad Soluble (Steba Biotech)
4.11.1.3. ProstAtak (Advantagene)
4.11.1.4. ARN-509 (Johnson & Johnson)
4.11.1.5. Custirsen (Oncogenex)
4.11.1.6. Prostvac (Bavarian Nordic)
4.11.1.7. Galeterone (Tokai Pharmaceuticals)
4.11.2. Phase II development
4.11.2.1. GDC-0068 (Roche)
4.11.2.2. PSMA ADC (Progenics Pharmaceuticals)
4.11.2.3. Apatorsen (OGX-427 – OncoGenex Pharmaceuticals)
4.11.3. Phase I
4.11.3.1. RG7450 (Roche)
4.11.3.2. BAY2010112 (Bayer Pharmaceuticals)
4.11.3.3. BPX-201 (Bellicum Pharmaceuticals)

5. The Prostate Cancer Devices Market, 2016-2026
5.1. The Prostate Cancer Devices Market 2014
5.2. The Prostate Cancer Devices Market Forecast, 2016-2026
5.3. The Market Shares of Leading Prostate Cancer Devices Submarkets, 2016-2026
5.4. The Radical Prostatectomy Market 2016-2026
5.4.1. Intuitive Surgical’s da Vinci Surgical System
5.5. The External Beam Radiation Therapy Market, 2016-2026
5.6. The Brachytherapy Market 2016-2026
5.7. The Cryotherapy Market 2016-2026
5.8. The HIFU Market, 2016-2026

6. The Leading Companies in the Prostate Cancer Therapies Market, 2016
6.1. The Leading Companies in the Prostate Cancer Drugs Market, 2016
6.2. Johnson & Johnson (J&J)
6.2.1. Sales and Performance Analysis, 2015
6.2.2. Pharmaceutical Segment Sales Analysis, 2015
6.2.3. Oncology Drugs Sales and Performance Analysis, 2015
6.2.4. Pharmaceutical Segment R&D Performance Analysis, 2015
6.2.5. Acquisition of Aragon Pharmaceuticals
6.3. AstraZeneca
6.3.1. Sales and Performance Analysis, 2015
6.3.2. Pharmaceutical Segment Sales & R&D Analysis by Segment, 2015
6.3.3. Oncology Drugs Sales and Performance Analysis, 2015
6.4. Sanofi
6.4.1. Sales and Performance Analysis, 2015
6.4.2. Sales and Performance Analysis by Segment, 2015
6.4.3. Oncology Sales and Performance Analysis, 2015
6.4.4. R&D Performance Analysis, 2015
6.4.5. Oncology Pipeline Portfolio
6.5. AbbVie
6.5.1. Sales and Performance Analysis, 2015
6.5.2. R&D Performance Analysis, 2015
6.5.3. Humira: From “First-In-Class” to “Best-In-Class”, 2015
6.5.4. Oncology Portfolio Pipeline Products, 2015
6.6. Leading Companies in the Prostate Cancer Devices Market 2016-2026
6.7. Varian Medical Systems
6.7.1. Sales and Performance Analysis, 2015
6.7.2. Oncology Segment Sales Analysis, 2015
6.7.3. Sales Analysis by Region, 2015
6.7.4. R&D Performance Analysis, 2015
6.7.5. Key Oncology Products, 2015
6.7.6. Varian and Siemens Partnership: Shaping the Future of Cancer Care
6.8. Elekta
6.8.1. Sales and Performance Analysis, 2015
6.8.2. Sales and Performance Analysis by Region, 2015
6.8.3. Elekta and Philips Establish Research Consortium
6.8.4. Product Launch and Development, 2015
6.9. Theragenics Corporation (acquired by Juniper Acquisition Corporation)
6.9.1. Theragenics Sales Performance Analysis, 2014
6.9.2. Theragenics Sales Performance by Operation, 2012
6.9.3. Sales and Performance Analysis by Business Unit, 2012
6.9.4. Mergers and Acquisitions
6.9.4.1. Juniper’s acquisition of Theragenics
6.9.4.2. Acquisition of US & Canadian Seed Business of Eckert & Ziegler BEBIG
6.9.4.3. Acquisition of Needle Tech Products
6.9.4.4. Acquisition of Galt Medical

7. The Leading National Markets, 2016-2026
7.1. Regional Breakdown of the Prostate Cancer Therapeutics Market, 2014
7.2. The Prostate Cancer Therapeutics Market: Regional Forecast, 2016-2026
7.3. Market Shares Forecasts of Leading National Prostate Cancer Therapeutics Markets, 2016-2026
7.4. The US Prostate Cancer Therapeutics Market 2016-2026
7.5. The European Prostate Cancer Therapeutics Market, 2014
7.6. The European Prostate Cancer Therapeutics Market, 2015-2025
7.6.1. The German Prostate Cancer Therapeutics Market, 2016-2026
7.6.2. The French Prostate Cancer Therapeutics Market, 2016-2026
7.6.3. The UK Prostate Cancer Therapeutics Market, 2015-2025
7.6.4. The Spanish Prostate Cancer Therapeutics Market, 2016-2026
7.6.5. The Italian Prostate Cancer Therapeutics Market, 2016-2026
7.7. The Japanese Prostate Cancer Therapeutics Market, 2016-2026
7.8. The Chinese Prostate Cancer Therapeutics Market, 2016-2026
7.9. The Brazilian Prostate Cancer Therapeutics Market, 2016-2026
7.10. The Russian Prostate Cancer Therapeutics Market, 2016-2026
7.11. The Indian Prostate Cancer Therapeutics Market, 2016-2026
7.12. The South Korean Prostate Cancer Therapeutics Market, 2016-2026
7.13. The Rest of the World Prostate Cancer Therapeutics Market, 2016-2026

8. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2016-2026
8.1. SWOT Analysis, 2016-2026
8.2. Strengths
8.2.1. Rapidly Ageing Male Populations Worldwide
8.2.2. A Number of Promising Pipeline Drug Candidates
8.2.3. Successful Partnerships Between Big and Small Pharmaceutical Companies Leading to New Products
8.3. Weaknesses
8.3.1. High Treatment Costs
8.3.2. High Levels of Phase III Attrition
8.4. Opportunities
8.4.1. Rising Incidence of Cancer
8.4.2. Development of Emerging Markets
8.5. Threats
8.5.1. Concerns about Efficacy and Toxicity of Drugs
8.5.2. Increase in Generic Competition
8.5.3. Healthcare Budget Restraints
8.6. Porter’s Five Force Analysis
8.6.1. Rivalry Among Competitors [High] 8.6.2. Threat of New Entrants [High] 8.6.3. Power of Suppliers [Low] 8.6.4. Power of Buyers [High] 8.6.5. Threat of Substitutes [Low]

9. Conclusions
9.1. The Prostate Cancer Therapeutics Market, 2016-2026
9.2. The US Will Remain the Largest National Market from 2016 to 2026
9.3. Concluding Remarks

10. Glossary

Table 1.1 Global Prostate Cancer Therapies Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2014-2020 (Altered Data)
Table 2.1 PSA Testing: Benefits and Limitations, 2016
Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2015
Table 2.3 Advantages and Disadvantages of Brachytherapy, 2016
Table 2.4 Advantages and Disadvantages of Radical Prostatectomy, 2016
Table 2.5 Advantages and Disadvantages of External Beam Radiation, 2016
Table 2.6 Advantages and Disadvantages of Cryotherapy, 2016
Table 2.7 Advantages and Disadvantages of HIFU, 2016
Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Segment, 2014
Table 3.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2016-2026
Table 4.1 The Prostate Cancer Drugs List: Key Brands, 2015
Table 4.2 The Prostate Cancer Drugs Market: Revenue ($m), Market Share (%) by Leading Drugs, 2015
Table 4.3 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.4 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.5 Market Shares (%) of the Leading Prostate Cancer Drugs, 2020 and 2026
Table 4.6 Sanofi: Taxotere Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.7 Sanofi: Taxotere Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.8 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.9 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.10 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.11 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.12 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2026
Table 4.13 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.14 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.15 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.16 Zoladex (AstraZeneca): Zoladex Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.17 Zoladex (AstraZeneca): Zoladex Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.18 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.19 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.20 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.21 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.22 Bayer: Xofigo Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.23 Bayer: Xofigo Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.24 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.25 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2026
Table 4.26 Key Drugs in Phase III Clinical Trials , 2016
Table 4.27 Key Drugs in Phase II Clinical Trials , 2016
Table 4.28 Key Drugs in Phase I Clinical Trials, 2016
Table 5.1 The Prostate Cancer Devices Market: Revenue ($m) and Market Share (%) by Segment, 2014
Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Segment, 2014-2020
Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Segment, 2020-2026
Table 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m) and Market Shares (%), 2014, 2020 and 2026
Table 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.6 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 5.7 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.8 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.9 The Brachytherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.10 The Brachytherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 5.11 The Cryotherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.12 The Cryotherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 5.13 The HIFU Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 5.14 The HIFU Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 6.1 Johnson & Johnson: Revenue ($m) and Revenue Share (%) by Segment, 2015
Table 6.2 Johnson & Johnson: Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
Table 6.3 Johnson & Johnson Pharmaceuticals: Revenue ($bn), and Revenue Shares (%) by Segment, 2015
Table 6.4 Johnson & Johnson Pharmaceuticals: Top 5 Best Selling Drugs, Revenue ($bn) and Revenue Share (%) 2015
Table 6.5 Johnson & Johnson: Oncology Pharmaceuticals Segment: Revenue ($m) and Percentage Share (%) by Drug, 2014-2015
Table 6.6 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2010-2015
Table 6.7 AstraZeneca: Revenue ($bn), AGR (%), 2010-2015
Table 6.8 AstraZeneca: Revenue ($bn), Revenue Shares (%) by Segment, 2015
Table 6.9 AstraZeneca: R&D Expenditure ($bn), Revenue ($bn) and R&D Expenditure as a Percentage of Sales, 2010-2015
Table 6.10 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2015
Table 6.11 AstraZeneca Oncology: Investigational Oncology Compounds in Mid to Late Stage Clinical Trials, 2015
Table 6.12 Sanofi: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
Table 6.13 Sanofi: Global Sales Revenue ($bn), Percentage Change (%) and Percentage Change at Constant Exchange Rates (%) by Region, 2014-2015
Table 6.14 Sanofi: Sale Revenue ($bn) and Revenue Shares (%) by Segment, 2015
Table 6.15 Sanofi: Revenue ($m) and Revenue Share (%) by Sub-Segments, 2015
Table 6.16 Sanofi: Oncology Sales ($m) and Revenue Share (%) by Product, 2015
Table 6.17 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2015
Table 6.18 Sanofi: Major Compounds from Sanofi’s Oncology Pipeline, 2015
Table 6.19 AbbVie: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
Table 6.20 AbbVie Main Products: Revenue ($m) 2013-2015
Table 6.21 AbbVie: Humira Indications by Regions, 2016
Table 6.22 Varian Medical Systems: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
Table 6.23 Varian Medical Systems: Revenue ($bn) and Revenue Share (%), 2015
Table 6.24 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Segment, 2015
Table 6.25 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Region, 2015
Table 6.26 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2015
Table 6.27 Elekta: Revenue ($bn), AGR (%) and CAGR (%) 2010-2015
Table 6.28 Elekta: Revenue ($m), by Country 2014-2015
Table 6.29 Theragenics: Revenue ($m), AGR (%) and CAGR (%) 2008-2012
Table 6.30 Theragenics: Revenue ($m) and Revenue Share (%) by Business Unit, 2012
Table 7.1 The Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Region, 2014
Table 7.2 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.3 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.4 Revenue ($m) and Market Shares (%) of the Leading Prostate Cancer Therapeutics National Markets, 2014, 2020 and 2026
Table 7.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.6 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.7 The European Prostate Cancer Therapeutics Markets: Revenue ($m), Market Share (%) by Country/Region, 2014
Table 7.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.9 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.10 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.11 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.12 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.13 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.14 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.15 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.16 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.17 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.18 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.19 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.20 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.21 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.22 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.23 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.24 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.25 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.26 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.27 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.28 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.29 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.30 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.31 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 7.32 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020
Table 7.33 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026
Table 8.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2016-2026

Figure 1.1 Prostate Cancer Therapeutics: Overview of Submarkets and Segments
Figure 2.1 Risk Factors Associated with Cancer Development
Figure 2.2 Global Proportion (%) of Newly Diagnosed Cancer by Type (Excluding Non-Melanoma Skin Cancer), 2012
Figure 2.3 Risk Factors Associated with Prostate Cancer Development
Figure 2.4 Prostate Cancer Incidence and Mortality in the US per 100,000 people, by Ethnicity, 2007-2011
Figure 2.5 Treatment Sequence for Prostate Cancer, 2016
Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) by Segment, 2014
Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Share (%) by Segment, 2014
Figure 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($m) by Leading Drugs, 2015
Figure 4.2 The Prostate Cancer Drugs Market: Market Share (%) by Leading Drugs, 2015
Figure 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m) and AGR (%), 2014-2026
Figure 4.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2020
Figure 4.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2026
Figure 4.6 Taxotere (Sanofi): Taxotere Revenue Forecast ($m) and AGR (%) 2014-2026
Figure 4.7 Sanofi: Jevtana Revenue Forecast ($m) and AGR (%) 2014-2026
Figure 4.8 AstraZeneca: Casodex Revenue Forecast ($m) and AGR (%) 2014-2026
Figure 4.9 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026
Figure 4.10 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026
Figure 4.11 AstraZeneca: Zoladex Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026
Figure 4.12 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%),2014-2026
Figure 4.13 Medivation/Astellas: Xtandi Revenue Forecast ($m) and AGR (%), 2014-2026
Figure 4.14 Bayer: Xofigo Revenue Forecast ($m) and AGR (%), 2014-2026
Figure 4.15 Other Prostate Cancer Drugs: Revenue Forecast ($m) and AGR (%), 2014-2026
Figure 5.1 Segmentation of the Prostate Cancer Devices Market, 2016
Figure 5.2 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2014
Figure 5.3 The Prostate Cancer Devices Market: Market Share (%) by Segment, 2014
Figure 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 5.5 The Prostate Cancer Devices Market Segments: Revenue ($m) Forecast, 2014, 2020, 2026
Figure 5.6 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2020
Figure 5.7 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2026
Figure 5.8 The Radical Prostatectomy Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 5.9 The External Beam Radiation Therapy Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 5.10 The Brachytherapy Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 5.11 The Cryotherapy Market Forecast: Revenue ($m), AGR (%), 2014-2026
Figure 5.12 The HIFU Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 6.1 Johnson & Johnson: Revenue Shares (%) by Segment, 2014
Figure 6.2 Johnson & Johnson: Historical Revenue ($bn) and AGR (%), 2010-2015
Figure 6.3 Johnson & Johnson Pharmaceuticals: Revenue ($bn) by Segment, 2015
Figure 6.4 Johnson & Johnson Pharmaceuticals: Revenue Share (%) by Segment, 2015
Figure 6.5 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Leading Drugs, 2015
Figure 6.6 Johnson & Johnson Oncology Pharmaceuticals Segment: Revenue Share (%) by Drug, 2014
Figure 6.7 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2015
Figure 6.8 AstraZeneca: Revenue ($bn), AGR (%), 2010-2015
Figure 6.9 AstraZeneca: Revenue ($bn) by Segment, 2015
Figure 6.10 AstraZeneca: Revenue Shares (%) by Segment, 2015
Figure 6.11 AstraZeneca Performance: R&D Costs ($bn) and Percentage of Sales (%), 2010-2015
Figure 6.12 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2015
Figure 6.13 AstraZeneca: Revenue Share (%) of Oncology Drugs, 2015
Figure 6.14 Sanofi: Historical Revenue ($bn) and AGR (%), 2010-2015
Figure 6.15 Sanofi: Global Sales Revenue ($bn) and Percentage Change (%) by Region, 2014-2015
Figure 6.16 Sanofi: Revenue ($bn) by Segment, 2015
Figure 6.17 Sanofi: Revenue Share (%) by Segment, 2015
Figure 6.18 Sanofi: Pharmaceutical Sub-segment Revenue Share (%), 2015
Figure 6.19 Sanofi: Oncology Revenue ($bn) by Product, 2015
Figure 6.20 Sanofi: Oncology Revenue Share (%) by Product, 2015
Figure 6.21 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Net Sales (%), 2010-2015
Figure 6.22 AbbVie: Revenue ($bn) and AGR (%), 2010-2015
Figure 6.23 AbbVie Main Products: Revenue ($m) Comparison, 2013-2015
Figure 6.24 AbbVie: Revenue Share (%) by Drug, 2015
Figure 6.25 Varian Medical Systems: Revenue ($bn) and AGR(%), 2010-2015
Figure 6.26 Varian Medical Systems: Revenue ($bn) by Segment, 2015
Figure 6.27 Varian Medical Systems: Revenue Share (%) by Segment, 2015
Figure 6.28 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2015
Figure 6.29 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2015
Figure 6.30 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2015
Figure 6.31 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2015
Figure 6.32 Elekta: Historical Revenue ($bn) and AGR (%), 2010-2015
Figure 6.33 Elekta: Historical Revenue ($m), by Country 2014-2015
Figure 6.34 Elekta: Revenue Share (%) by Country 2015
Figure 6.35 Theragenics: Revenue ($m) and AGR (%), 2008-2012
Figure 6.36 Theragenics: Revenue Share (%) by Operation, 2012
Figure 6.37 Theragenics: Revenue ($m) by Business Unit, 2012
Figure 6.38 Theragenics: Revenue Share (%) by Business Unit, 2012
Figure 7.1 The Prostate Cancer Therapeutics Market: Revenue ($m) by Region, 2014
Figure 7.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2014
Figure 7.3 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2020
Figure 7.4 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2026
Figure 7.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.6 The European Prostate Cancer Therapeutics Markets: Revenue ($m) by Country / Region, 2014
Figure 7.7 The European Prostate Cancer Therapeutics Markets: Market Share (%) by Country / Region, 2014
Figure 7.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2026
Figure 7.9 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.10 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026
Figure 7.11 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2026
Figure 7.12 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2026
Figure 7.13 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.14 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.15 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.16 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.17 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.18 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.19 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 7.20 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026
Figure 8.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2016-2026

★調査レポート[前立腺がん治療の世界市場2016-2026]販売に関する免責事項
★調査レポート[前立腺がん治療の世界市場2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆